Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Dana-Farber and Astellas Pharma Inc. have entered into a three-year collaboration to research and develop small molecule inhibitors of oncogenic
K-Ras for the treatment of cancer, including lung cancer.
The Joint Center for Cancer Precision Medicine has been established to create "precision medicine treatment pathways" for patients with advanced cancers and to speed the development of personalized therapies.
The human immune system is capable of recognizing cancer cells, but it doesn't effectively kill them: Dana-Farber discoveries show why this is so, and how drugs can be developed to overcome this immune suppression.
Lilly and Dana-Farber announce a three-year research collaboration to conduct clinical and preclinical studies on Lilly’s early-stage oncology compounds.
Our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through external collaborations and relationships with industry. Read more
Cancer Immunotherapy: Blocking the PD-1/PD-L1 Checkpoint
Dana-Farber has licensed a large patent portfolio covering PD-1 and PD-L1 to multiple pharmaceutical companies.
Evotec: Dana-Farber's Belfer Institute Collaboration
A partnership between Evotec and the Belfer Institute is aimed at discovering and commercializing novel cancer treatments based on epigenetic drug mechanisms.
Dana-Farber lab technologists invent blood handling device
Two Dana-Farber lab technologists have invented a patentable device that makes patient blood handling more efficient and safe. Its prototype is being commercially developed for further beta testing and marketing.
Tensha Therapeutics and Bromodomain Inhibition
A potent small molecule BET bromodomain inhibitor from the laboratory of Dana-Farber’s James Bradner, MD, licensed to Tensha Therapeutics, has entered clinical trials.
Gary Sclar, JD, Vice President, Dana-Farber Innovations
For general questions: firstname.lastname@example.orgFor Academic MTAs: email@example.com